SERTM1

Across TCGA pan-cancer cohorts, SERTM1 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SERTM1 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in kidney chromophobe (KICH), where higher SERTM1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SERTM1 expression acts as an unfavorable survival marker.

KICH, HNSC, and BLCA are the cancer types where SERTM1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KICH	DFS	Median	All	0.025	0.904	<.001	36	view →
HNSC	OS	Median	All	0.190	0.688	<.001	24	view →
BLCA	OS	Median	III,IV	0.130	0.684	<.001	24	view →
COAD	OS	Median	III,IV	0.159	0.692	.021	12	view →
UCS	DFS	Median	All	0.136	0.523	.034	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SERTM1–KICH (DFS)

Open the KICH breakdown →